ERBB2 and triple-negative breast carcinoma: Several studies have suggested that luminal A breast cancer has the best prognosis, whereas human epidermal growth factor receptor 2 (Her-2) and triple-negative breast cancer (TNBC) have higher rates of local recurrence [3–6].